State of New Jersey Common Pension Fund D raised its holdings in Tilray Inc (NASDAQ:TLRY - Get Rating) by 23.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 593,544 shares of the company's stock after buying an additional 112,249 shares during the period. State of New Jersey Common Pension Fund D owned about 0.10% of Tilray worth $1,632,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of TLRY. JPMorgan Chase & Co. raised its stake in Tilray by 63.2% in the first quarter. JPMorgan Chase & Co. now owns 266,929 shares of the company's stock valued at $2,073,000 after buying an additional 103,379 shares during the period. Raymond James & Associates increased its stake in shares of Tilray by 7.4% during the first quarter. Raymond James & Associates now owns 103,410 shares of the company's stock worth $803,000 after purchasing an additional 7,135 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in shares of Tilray by 77.8% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 148,682 shares of the company's stock worth $1,155,000 after purchasing an additional 65,079 shares during the period. Cetera Advisor Networks LLC bought a new position in shares of Tilray during the first quarter worth approximately $82,000. Finally, Private Advisor Group LLC increased its stake in shares of Tilray by 25.6% during the first quarter. Private Advisor Group LLC now owns 51,937 shares of the company's stock worth $404,000 after purchasing an additional 10,587 shares during the period. Institutional investors own 11.59% of the company's stock.
Tilray Trading Up 3.4 %
Shares of TLRY stock opened at $3.05 on Friday. The stock's fifty day moving average price is $3.36 and its two-hundred day moving average price is $3.45. The company has a market cap of $1.88 billion, a PE ratio of -2.90 and a beta of 2.67. Tilray Inc has a fifty-two week low of $2.52 and a fifty-two week high of $9.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.35 and a current ratio of 1.91.
Tilray (NASDAQ:TLRY - Get Rating) last issued its earnings results on Monday, January 9th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The business had revenue of $144.10 million during the quarter, compared to analyst estimates of $157.21 million. Tilray had a negative net margin of 89.96% and a negative return on equity of 5.10%. The firm's revenue was down 7.1% on a year-over-year basis. Equities analysts predict that Tilray Inc will post -0.34 EPS for the current fiscal year.
Insider Activity at Tilray
In related news, Director Brendan Kennedy sold 350,000 shares of the firm's stock in a transaction on Monday, November 7th. The stock was sold at an average price of $3.78, for a total transaction of $1,323,000.00. Following the sale, the director now owns 6,224,196 shares of the company's stock, valued at approximately $23,527,460.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.54% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. Sanford C. Bernstein assumed coverage on Tilray in a research note on Tuesday, November 1st. They set a "market perform" rating and a $3.90 target price on the stock. Alliance Global Partners reduced their price target on Tilray from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Monday, January 9th. Cantor Fitzgerald increased their price target on Tilray from $4.15 to $4.50 and gave the stock a "neutral" rating in a research report on Monday, October 10th. Haywood Securities reduced their price target on Tilray to $3.50 in a research report on Thursday, October 13th. Finally, Barclays reduced their price target on Tilray from $4.50 to $2.00 and set an "underweight" rating on the stock in a research report on Friday, September 30th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $5.08.
Tilray Company Profile
(
Get Rating)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
